Related Experiment Video

Updated: Jun 8, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Treatment of malignant pleural mesothelioma: current status and future directions

X Dhalluin1, A Scherpereel

  • 1Pneumologie et Oncologie Thoracique, Hôpital Calmette - CHRU de Lille, Lille Cedex, France.

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|October 19, 2010
PubMed

Insights

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis, often linked to asbestos exposure. This review summarizes 2010 therapeutic strategies and future treatments for MPM patients.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Respiratory Medicine

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a historically poor prognosis.
  • Increasing incidence of MPM is linked to past asbestos exposure, highlighting its public health significance.
  • Current treatment options for MPM remain suboptimal, necessitating advancements in therapeutic strategies and predictive tools.

Purpose of the Study:

  • To provide clinicians with updated information on the latest therapeutic strategies for malignant pleural mesothelioma (MPM) patients as of 2010.
  • To summarize the European Respiratory Society (ERS) and European Society of Thoracic Surgeons (ESTS) guidelines for MPM management.
  • To review emerging future directions in MPM treatment, including targeted therapies, gene therapy, and cell therapy.

Main Methods:

  • Literature review focusing on therapeutic strategies for malignant pleural mesothelioma.
  • Summarization of recently published European guidelines (ERS and ESTS) for MPM management.
  • Exploration of future treatment modalities such as targeted therapies, gene therapy, and cell therapy.

Main Results:

  • The review consolidates current (2010) therapeutic approaches for MPM.
  • Key recommendations from ERS and ESTS taskforce guidelines are presented.
  • Potential future treatment avenues including targeted, gene, and cell therapies are discussed.

Conclusions:

  • Optimal treatment for malignant pleural mesothelioma is not yet established.
  • There is a critical need for novel therapies and predictive tools in MPM management.
  • Future research directions focus on personalized medicine approaches like targeted, gene, and cell therapies for MPM.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...